| Market Capitalization (Millions $) |
48 |
| Shares
Outstanding (Millions) |
26 |
| Employees |
120 |
| Revenues (TTM) (Millions $) |
27 |
| Net Income (TTM) (Millions $) |
-92 |
| Cash Flow (TTM) (Millions $) |
5 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Celularity Inc. is a biotechnology company based in Warren, New Jersey, United States. It was founded in 2017 by Dr. Robert Hariri and Peter Diamandis with a mission to revolutionize the field of regenerative medicine through the development of innovative cellular therapies. The company focuses on harnessing the power of placental cells to create transformative treatments for a variety of diseases, including cancer, infectious diseases, and autoimmune disorders.
The uniqueness of Celularity comes from its proprietary platform technology, which utilizes placental cells obtained from full-term deliveries. These cells possess a remarkable ability to regenerate tissues and modulate immune responses, making them ideal candidates for therapeutic applications. Celularityes platform technology involves the isolation and characterization of placental cells, including placental hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which can then be expanded in culture to generate large quantities of cells for therapeutic use.
Celularityes pipeline includes several cellular therapies that are currently in clinical trials or preclinical development. One of its most promising candidates is Cynk-001, an off-the-shelf, allogeneic natural killer (NK) cell therapy derived from placental HSCs. NK cells are a type of immune cell that can directly kill cancer cells and virally-infected cells without prior sensitization, making them ideal for cancer immunotherapy. Cynk-001 has shown great promise in clinical trials for various types of cancer, including multiple myeloma, acute myeloid leukemia, and ovarian cancer.
In addition to cellular therapies, Celularityes platform technology has potential applications in other areas. The company has developed a placental-derived extracellular matrix (ECM) product called Axiologik, which has demonstrated the ability to promote tissue repair and regeneration. Axiologik is being evaluated as a potential treatment for chronic wounds, burns, and other tissue injuries.
Celularity Inc. is a privately-held company that has received significant investment from notable biotech investors, including United Therapeutics Corporation, Sorrento Therapeutics, and Dreyfus Health Foundation. The company has also formed strategic partnerships with other industry leaders, such as United Parcel Service (UPS), for the development of logistics and supply chain solutions for the delivery of cellular therapies.
Overall, Celularity Inc. is a cutting-edge biotech company that is at the forefront of the regenerative medicine field. Its innovative use of placental cells and platform technology has the potential to transform the treatment of a variety of diseases and improve patient outcomes.
Company Address: 170 Park Ave Florham Park 7932 NJ
Company Phone Number: 768-2170 Stock Exchange / Ticker: NASDAQ CELU
|
0.13% 
16.92 %